Journal of Statistics: Advances in Theory and Applications[1] AIFA, Rapporto AIFA sulla Sorveglianza dei vaccini COVID-19, no.
5, 27/12/2020 - 26/05/2021, (2021a).
https://www.aifa.gov.it/documents/20142/1315190/Rapporto_sorveglianza_
vaccini_COVID-19_5.pdf
[2] AIFA, Rapporto Annuale Sulla Sicurezza dei Vaccini Anti-COVID-19,
27/12/2020 - 26/12/2021, (2022).
https://www.aifa.gov.it/documents/20142/1315190/Rapporto_annuale_su_si
curezza_vaccini%20anti-COVID-19.pdf
[3] M. Baccini, B. Cheli, R. Foschi, A. Iodice, L. Melacarne, B. Pinto
and E. Serravalle, Considerazioni critiche sul confronto tra decessi
osservati e attesi dopo la vaccinazione nel 10° Rapporto AIFA sulla
Sorveglianza dei vaccine COVID-19, Discussion Papers del Dipartimento
di Economia e Management, Universita di Pisa, 286 (2022).
http://www.ec.unipi.it/ricerca/discussion-papers
[4] B. Cheli, R. Foschi, A. Iodice and E. Serravalle, Considerazioni
critiche sul confronto tra decessi attesi e osservati dopo la
vaccinazione contenuto nel 5° Rapporto AIFA sulla Sorveglianza dei
vaccini COVID-19, Discussion Paper Dipartimento di Economia e
Management, Universita di Pisa, 285 (2022).
http://www.ec.unipi.it/ricerca/discussion-papers
[5] L. Hazell and S. A. Shakir, Under-reporting of adverse drug
reactions, Drug Safety 29(5) (2006), 385-396.
DOI: https://doi.org/10.2165/00002018-200629050-00003
[6] F. R. Varallo, S. de Oliveira Paim Guimarães, S. Abjaude and P.
de Carvalho Mastroianni, Causes for the underreporting of adverse drug
events by health professionals: A systematic review, Revista da Escola
de Enfermagem da USP 48(4) (2014), 739-747.
DOI: https://doi.org/10.1590/s0080-623420140000400023
[7] O. Mahaux, V. Bauchau and L. Van Holle, Pharmacoepidemiological
considerations in observed-to-expected analyses for vaccines,
Pharmacoepidemiology and Drug Safety 25(2) (2016), 215-222.
DOI: https://doi.org/10.1002/pds.3918
[8] M. Gahr, J. Eller, B. J. Connemann and C. Schönfeldt-Lecuona,
Underreporting of adverse drug reactions: Results from a survey among
physicians, European Psychiatry 41(S1) (2017), S369.
DOI: https://doi.org/10.1016/j.eurpsy.2017.02.377
[9] A. Patrignani, G. Palmieri, N. Ciampani, V. Moretti, A. Mariani
and L. Racca, Under-reporting of adverse drug reactions, a problem
that also involves medicines subject to additional monitoring,
Preliminary data from a single-center experience on novel oral
anticoagulants, Journal of Italian Cardiology 19(1) (2018), 54-61.
DOI: https://doi.org/10.1714/2852.28779
[10] A. Dutta, A. Banerjee, S. Basu and S. Chaudhry, Analysis of
under-reporting of Adverse Drug Reaction: Scenario in India and
neighbouring countries, IP International Journal of Comprehensive and
Advanced Pharmacology 5(3) (2020), 118-124.
DOI: https://doi.org/10.18231/j.ijcaap.2020.025
[11] J. Inch, M. C. Watson, S. Anakwe-Umeh, Patient versus Healthcare
Professional Spontaneous Adverse Drug Reaction Reporting, Drug Safety
35(10) (2012), 807-818.
DOI: https://doi.org/10.1007/BF03261977
[12] A. Sandberg, V. Salminen, S. Heinonen and M. Sivén,
Under-Reporting of Adverse Drug Reactions in Finland and Healthcare
Professionals’ Perspectives on How to Improve Reporting,
Healthcare 10(6) (2022); Article 1015.
DOI: https://doi.org/10.3390/healthcare10061015
[13] T. T. Shimabukuro, M. Nguyen, D. Martin and F. DeStefano, Safety
monitoring in the Vaccine Adverse Event Reporting System (VAERS),
Vaccine 33(36) (2015), 4398-4405.
DOI: https://doi.org/10.1016/j.vaccine.2015.07.035
[14] Julianne Gee, Paige Marquez, John Su, Geoffrey M. Calvert,
Ruiling Liu, Tanya Myers, Narayan Nair, Stacey Martin, Thomas Clark,
Lauri Markowitz, Nicole Lindsey, Bicheng Zhang, Charles Licata, Amelia
Jazwa, Mark Sotir and Tom Shimabukuro, US Department of Health and
Human Disease Control and Prevention (2021) “First Month of
COVID-19 Vaccine Safety Monitoring – United States, December
14, 2020 – Jan 13, 2021â€. MMWR Morbidity and Mortality
Weekly Reports, Feb 26 70(8) (2021), 283-288.
DOI: https://doi.org/10.15585/mmwr.mm7008e3
[15] T. Shimabukuro, COVID-19 Vaccine safety updates - Advisory
Committee on Immunization Practices (ACIP), June 23, 2021, Tom
Shimabukuro, MD, MPH, MBA, Vaccine Safety Team, CDC COVID-19 Vaccine
Task Force, 2021.
https://www.cdc.gov/vaccines/acip/meetings/slides-2021-06.html
[16] AIFA, Rapporto AIFA sulla Sorveglianza dei vaccini COVID-19, no.
2, 27/12/2020 - 26/02/2021 (2021b).
https://www.aifa.gov.it/en/-/secondo-rapporto-aifa-sullasorveglianza-d
ei-vaccini-covid-19
